Evidence map›Paper›PMID 25219354›Full record

ArticleEpilepsy research2014

Medication side effects among people with epilepsy taking phenobarbital in Zambia.

Melissa A Elafros, Esther Bui, Gretchen L Birbeck

Open access · bronzeAbstract read
In one paragraph

Article in Epilepsy research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Melissa A ElafrosMichigan State University, International Neurologic & Psychiatric Epidemiology Program (INPEP), East Lansing, MI, USA; Michigan State University, College of Human Medicine, East Lansing, MI, USA.
Esther BuiSunnybrook Health Sciences Centre, Department of Medicine, Toronto, Ontario, Canada.
Gretchen L BirbeckChikankata Hospital, Epilepsy Care Team, Mazabuka, Zambia; University of Rochester, Department of Neurology, Epilepsy Division, Rochester, NY, USA; University of Rochester, Department of Public Health, Rochester, NY, USA. Electronic address: gretchen_birbeck@urmc.rochester.edu.
Michigan State University · USSunnybrook Health Science Centre · CAUniversity of Rochester · US

Funding

Epilepsy-associated stigma in ZambiaR21NS048060 · NINDS · MICHIGAN STATE UNIVERSITY · PI BIRBECK, GRETCHEN LANO · 2003 to 2005
$341k
NINDS NIH HHS R21 NS048060NINDS NIH HHS R21NS48060
6 · The paper itself

Abstract

Phenobarbital remains one of the most widely used antiepileptic drugs worldwide, yet there are limited data regarding side effects associated with its use in routine clinical care settings in low-income countries. Available data suggests that phenobarbital is as effective as other first-line drugs for treating tonic-clonic seizures, but side effect reports differ widely between high and low-income settings. A better understanding of phenobarbital side effect profile and severity in low-income settings is warranted given its role in efforts to decrease the epilepsy treatment gap. We used the Liverpool adverse events profile (LEAP) to assess side effects in consecutive patients with epilepsy on phenobarbital seeking care in rural Zambia. Data regarding age, gender, medication dose, and medication adherence were also collected. T-tests and Spearman's correlation coefficient were used to assess predictors of LEAP score and medication adherence. Thirty-five patients receiving a mean dose of 2.1mg/kg/day (SD: 2.78 mg/kg/day) of phenobarbital were assessed. All participants reported at least one side effect in the previous four weeks with a median of 6 symptoms (IQR: 4-8) and a mean side effects score of 28/76 (SD: 5.38). Over half reported sleepiness and dizziness. Memory problems and depression were also common (both 46%). Total LAEP score was not associated with age (p=0.88), gender (p=0.17), or phenobarbital dose (p=0.13). Medication adherence was not associated with side effects total score (p=0.56). Rural Zambian adults taking phenobarbital at doses recommended by the World Health Organization report a significant number of side effects. The most common side effects reported were similar to those reported in high-income countries. The significant burden of phenobarbital-associated side effects in this African cohort is in contrast to data from non-randomized clinical trials in China that reported phenobarbital to be well-tolerated with few side effects. Additional investigations regarding phenobarbital side effects during routine care in low income settings is warranted.

Indexed as

AdolescentAdultAnticonvulsantsEpilepsyFemaleHumansMaleNervous System DiseasesPhenobarbitalSickness Impact ProfileStatistics, NonparametricTreatment OutcomeYoung AdultZambiaAnticonvulsantsPhenobarbitalAdverse effectsAntiepileptic drugsLow-income settingSub-Saharan AfricaTreatment gapTreatment outcome

Identifiers

PMID25219354
PMCPMC4194251
OpenAlexW2009244515

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.